BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794 [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786]
URL: https://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
Number Citing Articles
1
Jae Jin Lee, Martine Extermann. Cancer and Chronic Conditions2016; : 131 doi: 10.1007/978-981-10-1844-2_5
2
G. de Stefano, V. Iodice, N. Farella. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case ReportJournal of Gastrointestinal Cancer 2015; 46(4): 430 doi: 10.1007/s12029-015-9720-5
3
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi, Andrea Lorenzo Inghilesi. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upWorld Journal of Hepatology 2015; 7(8): 1041-1053 doi: 10.4254/wjh.v7.i8.1041
4
Xue-Fen Lei, Yang Ke, Tian-Hao Bao, Hao-Ran Tang, Xue-Song Wu, Zhi-Tian Shi, Jie Lin, Zhi-Xian Zhang, Hou Gu, Lin Wang. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative studyWorld Journal of Clinical Cases 2018; 6(5): 74-83 doi: 10.12998/wjcc.v6.i5.74
5
Gennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, Emanuela Ferraro, Antonio Mazzocca, Ferruccio De Rose, Gianfranco Filippelli, Ines Abbate, Mario Brandi. Sorafenib: 10 years after the first pivotal trialFuture Oncology 2015; 11(13): 1863 doi: 10.2217/fon.15.85
6
Thomas Reiberger, Yunching Chen, Rakesh R Ramjiawan, Tai Hato, Christopher Fan, Rekha Samuel, Sylvie Roberge, Peigen Huang, Gregory Y Lauwers, Andrew X Zhu, Nabeel Bardeesy, Rakesh K Jain, Dan G Duda. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosisNature Protocols 2015; 10(8): 1264 doi: 10.1038/nprot.2015.080
7
Yadi Liao, Yun Zheng, Wei He, Qijiong Li, Jingxian Shen, Jian Hong, Ruhai Zou, Jiliang Qiu, Binkui Li, Yunfei Yuan. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrenceOncology Letters 2017; 13(2): 984 doi: 10.3892/ol.2016.5525
8
Seong K. Na, Sun Y. Yim, Sang J. Suh, Young K. Jung, Ji H. Kim, Yeon S. Seo, Hyung J. Yim, Jong E. Yeon, Kwan S. Byun, Soon H. Um. ALBI versus Child‐Pugh grading systems for liver function in patients with hepatocellular carcinomaJournal of Surgical Oncology 2018; 117(5): 912 doi: 10.1002/jso.24992
9
Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Ming‐Yen Hsieh, Nei‐Jen Hou, I‐Hung Lin, Po‐Cheng Liang, Yi‐Shan Tsai, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatmentThe Kaohsiung Journal of Medical Sciences 2019; 35(10): 624 doi: 10.1002/kjm2.12105
10
Federica Cosso, Daniele Lavacchi, Sara Fancelli, Enrico Caliman, Marco Brugia, Gemma Rossi, Costanza Winchler, Serena Pillozzi, Lorenzo Antonuzzo. Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancerAnti-Cancer Drugs 2023; 34(3): 451 doi: 10.1097/CAD.0000000000001410
11
Wen‐Tsan Chang, Sheng‐Nan Lu, Kung‐Ming Rau, Ching‐Shan Huang, King‐Teh Lee. Increased cumulative doses and appearance of hand‐foot skin reaction prolonged progression free survival in sorafenib‐treated advanced hepatocellular carcinoma patientsThe Kaohsiung Journal of Medical Sciences 2018; 34(7): 391 doi: 10.1016/j.kjms.2018.03.006
12
Brittany Dewdney, Alexandra Roberts, Liang Qiao, Jacob George, Lionel Hebbard. A Sweet Connection? Fructose’s Role in Hepatocellular CarcinomaBiomolecules 2020; 10(4): 496 doi: 10.3390/biom10040496
13
Sae Hwan Lee, Il Han Song, Ran Noh, Ha Yan Kang, Suk Bae Kim, Soon Young Ko, Eoum Seok Lee, Seok Hyun Kim, Byung Seok Lee, An Na Kim, Hee Bok Chae, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Jae Dong Lee, Heon Young Lee. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutionsBMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1273-2
14
Shijie Wang, Yiting Wang, Jiangtao Yu, Huaxing Wu, Yanming Zhou. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-AnalysisCancers 2022; 14(22): 5525 doi: 10.3390/cancers14225525
15
Céline Lescure, Florian Estrade, Maud Pedrono, Boris Campillo-Gimenez, Samuel Le Sourd, Marc Pracht, Xavier Palard, Héloïse Bourien, Léa Muzellec, Thomas Uguen, Yan Rolland, Etienne Garin, Julien Edeline. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular CarcinomaCancers 2021; 13(15): 3794 doi: 10.3390/cancers13153794
16
Parakh Gulati, Sunil Taneja, Ajay Duseja, Virendra Singh. Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Should we extend the boundaries?Hepatology 2022; 76(4): E80 doi: 10.1002/hep.32554
17
Daniele Lavacchi, Giandomenico Roviello, Alessia Guidolin, Silvia Romano, Jacopo Venturini, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Elisa Pellegrini, Marco Brugia, Serena Pillozzi, Lorenzo Antonuzzo. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal CancerInternational Journal of Molecular Sciences 2023; 24(6): 5840 doi: 10.3390/ijms24065840
18
Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinomaHepatology Research 2015; 45(10) doi: 10.1111/hepr.12480
19
Xuying Wan, Xiaofeng Zhai, Zhenlin Yan, Pinghua Yang, Jun Li, Dong Wu, Kui Wang, Yong Xia, Feng Shen. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinomaOncotarget 2016; 7(50): 83806 doi: 10.18632/oncotarget.11514
20
Lei Xu, Lin Chen, Bin Zhang, Zhicheng Liu, Qiumeng Liu, Huifang Liang, Yifa Chen, Xiaoping Chen, Chao Leng, Bixiang Zhang. Alkaline phosphatase combined with γ-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitorsFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1115706